Analyst increased price target and rating for Ligand Pharmaceuticals.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst increased price target and rating for Ligand Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
-
Royal Bank of Canada
financial institution in Canada
Related events
- Analyst raised price target and gave outperform rating for Aramark on August 19, 2026.
- Jefferies Financial Group reaffirmed a 'buy' rating and issued a $45.00 target price for NewAmsterdam Pharma, Inc.
- Analysts from Raymond James Financial, Desjardins, and Royal Bank of Canada increased price targets and ratings for Exchange Income Co.
- Analyst upgraded rating and set price target for Pound Medical, and Royal Bank of Canada increased its share holdings.
- Royal Bank of Canada reaffirmed rating, Citigroup began coverage, and Morgan Stanley boosted price target on Arrowhead Pharmaceuticals.